1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Introduction
2.2. Define: Research Objective
2.3. Determine: Research Design
2.4. Prepare: Research Instrument
2.5. Collect: Data Source
2.6. Analyze: Data Interpretation
2.7. Formulate: Data Verification
2.8. Publish: Research Report
2.9. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Proliferation in the number of people suffering from cancer
5.1.1.2. Growing geriatric population with hypertension and diabetes
5.1.1.3. Increasing lifestyle changes including smoking, drinking, and consumption of processed food
5.1.2. Restraints
5.1.2.1. Risk of complications associated with treatment
5.1.3. Opportunities
5.1.3.1. Availability of novel drugs and the presence of a strong pipeline
5.1.3.2. Increasing research and development investment coupled with collaborations among manufacturers
5.1.4. Challenges
5.1.4.1. Stringent regulatory policies
5.2. Cumulative Impact of COVID-19

6. Kidney Cancer Drugs Market, by Type
6.1. Introduction
6.2. Chromophobe
6.3. Clear Cell
6.4. Collecting Duct
6.5. Oncocytic
6.6. Papillary

7. Kidney Cancer Drugs Market, by Pharmacologic Class
7.1. Introduction
7.2. Angiogenesis Inhibitors
7.3. Cytokine Immunotherapy (IL-2)
7.4. Monoclonal Antibodies
7.5. mTOR Inhibitors

8. Kidney Cancer Drugs Market, by Therapeutic Class
8.1. Introduction
8.2. Immunotherapy
8.3. Targeted Therapy

9. Americas Kidney Cancer Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Kidney Cancer Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand

11. Europe, Middle East & Africa Kidney Cancer Drugs Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Bayer AG
13.2. Bristol-Myers Squibb Company
13.3. Eisai Co., Ltd.
13.4. Exelixis, Inc.
13.5. F. Hoffmann La Roche Ltd.
13.6. Genentech, Inc.
13.7. GlaxoSmithKline plc
13.8. Novartis AG
13.9. Pfizer Inc.
13.10. Prometheus Laboratories Inc.

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. GLOBAL KIDNEY CANCER DRUGS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL KIDNEY CANCER DRUGS MARKET: MARKET DYNAMICS
FIGURE 3. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2020 VS 2027 (%)
FIGURE 4. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2020 VS 2027 (USD MILLION)
FIGURE 5. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2027
FIGURE 6. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CHROMOPHOBE, 2018-2027 (USD MILLION)
FIGURE 7. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CHROMOPHOBE, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 8. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CLEAR CELL, 2018-2027 (USD MILLION)
FIGURE 9. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CLEAR CELL, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 10. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY COLLECTING DUCT, 2018-2027 (USD MILLION)
FIGURE 11. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY COLLECTING DUCT, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 12. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ONCOCYTIC, 2018-2027 (USD MILLION)
FIGURE 13. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ONCOCYTIC, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 14. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY PAPILLARY, 2018-2027 (USD MILLION)
FIGURE 15. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY PAPILLARY, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 16. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2020 VS 2027 (%)
FIGURE 17. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2020 VS 2027 (USD MILLION)
FIGURE 18. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2027
FIGURE 19. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2027 (USD MILLION)
FIGURE 20. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 21. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CYTOKINE IMMUNOTHERAPY (IL-2), 2018-2027 (USD MILLION)
FIGURE 22. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CYTOKINE IMMUNOTHERAPY (IL-2), BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 23. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2027 (USD MILLION)
FIGURE 24. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 25. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY MTOR INHIBITORS, 2018-2027 (USD MILLION)
FIGURE 26. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 27. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2020 VS 2027 (%)
FIGURE 28. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2020 VS 2027 (USD MILLION)
FIGURE 29. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2027
FIGURE 30. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2027 (USD MILLION)
FIGURE 31. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 32. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2027 (USD MILLION)
FIGURE 33. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 34. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 35. ARGENTINA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 36. BRAZIL KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 37. CANADA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 38. MEXICO KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 39. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 40. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 41. AUSTRALIA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 42. CHINA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 43. INDIA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 44. INDONESIA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 45. JAPAN KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 46. MALAYSIA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 47. PHILIPPINES KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 48. SINGAPORE KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 49. SOUTH KOREA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 50. TAIWAN KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 51. THAILAND KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 52. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 53. FRANCE KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 54. GERMANY KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 55. ITALY KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 56. NETHERLANDS KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 57. QATAR KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 58. RUSSIA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 59. SAUDI ARABIA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 60. SOUTH AFRICA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 61. SPAIN KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 62. UNITED ARAB EMIRATES KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 63. UNITED KINGDOM KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 64. GLOBAL KIDNEY CANCER DRUGS MARKET: FPNV POSITIONING MATRIX
FIGURE 65. GLOBAL KIDNEY CANCER DRUGS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 66. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL KIDNEY CANCER DRUGS MARKET, BY TYPE

List of Tables

TABLE 1. GLOBAL KIDNEY CANCER DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 4. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CHROMOPHOBE, BY REGION, 2018-2027 (USD MILLION)
TABLE 5. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CLEAR CELL, BY REGION, 2018-2027 (USD MILLION)
TABLE 6. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY COLLECTING DUCT, BY REGION, 2018-2027 (USD MILLION)
TABLE 7. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ONCOCYTIC, BY REGION, 2018-2027 (USD MILLION)
TABLE 8. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY PAPILLARY, BY REGION, 2018-2027 (USD MILLION)
TABLE 9. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2027 (USD MILLION)
TABLE 10. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2018-2027 (USD MILLION)
TABLE 11. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CYTOKINE IMMUNOTHERAPY (IL-2), BY REGION, 2018-2027 (USD MILLION)
TABLE 12. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2027 (USD MILLION)
TABLE 13. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2027 (USD MILLION)
TABLE 14. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2027 (USD MILLION)
TABLE 15. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2027 (USD MILLION)
TABLE 16. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2027 (USD MILLION)
TABLE 17. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 18. ARGENTINA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 19. BRAZIL KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 20. CANADA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 21. MEXICO KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 22. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 23. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 24. AUSTRALIA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 25. CHINA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 26. INDIA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 27. INDONESIA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 28. JAPAN KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 29. MALAYSIA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 30. PHILIPPINES KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 31. SINGAPORE KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 32. SOUTH KOREA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 33. TAIWAN KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 34. THAILAND KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 35. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 36. FRANCE KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 37. GERMANY KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 38. ITALY KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 39. NETHERLANDS KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 40. QATAR KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 41. RUSSIA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 42. SAUDI ARABIA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 43. SOUTH AFRICA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 44. SPAIN KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 45. UNITED ARAB EMIRATES KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 46. UNITED KINGDOM KIDNEY CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 47. GLOBAL KIDNEY CANCER DRUGS MARKET: SCORES
TABLE 48. GLOBAL KIDNEY CANCER DRUGS MARKET: BUSINESS STRATEGY
TABLE 49. GLOBAL KIDNEY CANCER DRUGS MARKET: PRODUCT SATISFACTION
TABLE 50. GLOBAL KIDNEY CANCER DRUGS MARKET: RANKING
TABLE 51. GLOBAL KIDNEY CANCER DRUGS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 52. GLOBAL KIDNEY CANCER DRUGS MARKET: MERGER & ACQUISITION
TABLE 53. GLOBAL KIDNEY CANCER DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 54. GLOBAL KIDNEY CANCER DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 55. GLOBAL KIDNEY CANCER DRUGS MARKET: INVESTMENT & FUNDING
TABLE 56. GLOBAL KIDNEY CANCER DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 57. GLOBAL KIDNEY CANCER DRUGS MARKET: LICENSE & PRICING

Companies Mentioned

Bayer AG
Bristol-Myers Squibb Company
Eisai Co., Ltd.
Exelixis, Inc.
F. Hoffmann La Roche Ltd.
Genentech, Inc.
GlaxoSmithKline plc
Novartis AG
Pfizer Inc.
Prometheus Laboratories Inc.